We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV - Free Report) announced that it is exercising its exclusive right and acquiring private biotech company Mitokinin, which is making a novel treatment for Parkinson's Disease (“PD”).
Mitokinin’s lead pipeline compound is a selective PINK1 activator that addresses mitochondrial dysfunction, which plays an instrumental role in the pathogenesis and progression of PD. Mutations in the PINK1 gene can cause a loss of the PINK1 function, which can result in familial forms of PD. Targeting the PINK1 gene can provide a novel approach for treating PD. Pre-clinical data has shown that the compound can selectively enhance the active form of the PINK1 gene, which amends mitochondrial damage and re-instates mitochondrial function
The candidate, if successfully developed, could be a potential new treatment option for PD. Therapies available to treat PD presently reduce the symptoms of the disease but none prevent the progression of the disease.
Year to date, AbbVie’s shares have lost 8.8% against the industry’s 2.9% rise.
Image Source: Zacks Investment Research
For the deal, AbbVie is making a payment of $110 million to Mitokinin shareholders who will also remain eligible for potential development/commercial milestone payments of up to $545 million
The acquisition, if successfully closed, will strengthen AbbVie’s neuroscience pipeline.
AbbVie’s neuroscience portfolio includes mature drugs like Vraylar and Botox as well as newer drugs like Ubrelvy and Qulipta. While Vraylar is approved for schizophrenia and manic or mixed episodes associated with bipolar I disorder, Botox is approved for several neuroscience indications including chronic migraine, and spastic disorders among others. AbbVie’s neuroscience drugs generated sales of $3.1 billion in the first half of 2023, up 13.8% year over year.
AbbVie also has another PD candidate in its neuroscience pipeline called ABBV-951 for treating motor fluctuations in patients with advanced PD. In March this year, the FDA issued a complete response letter (CRL) to AbbVie’s new drug application (“NDA”) seeking approval for ABBV-951.
ABBV-951 is a solution of carbidopa and levodopa prodrugs, which are the standard of care for PD patients. ABBV-951 has been designed to offer continuous subcutaneous delivery of CD/LD prodrugs through a pump device and offer a better patient experience. In the CRL, the FDA has asked for some extra information about the pump device used to administer the medicine. The FDA has not requested any additional efficacy/safety studies.
In the past 60 days, the consensus estimate for Alpine Immune Sciences’ 2023 loss has narrowed from $1.43 per share to $1.18 per share, while the same for 2024 has narrowed from $1.73 per share to $1.47 per share. Year to date, shares of Alpine Immune Sciences have rallied 65.5%.
ALPN’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative earnings surprise of 79.65%.
In the past 60 days, the loss per share estimate for Aurinia Pharmaceuticals for 2023 has narrowed from 64 cents per share to 58 cents per share, while that for 2024 has narrowed from 37 cents to 27 cents. Year to date, shares of Aurinia Pharmaceuticals have gained 68.5%.
Earnings of Aurinia Pharmaceuticals beat estimates in all the last four quarters, delivering an earnings surprise of 45.61% on average.
In the past 60 days, the Zacks Consensus Estimate for Corcept’s earnings has increased from 75 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 81 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 30.4% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average earnings surprise of 6.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker
AbbVie (ABBV - Free Report) announced that it is exercising its exclusive right and acquiring private biotech company Mitokinin, which is making a novel treatment for Parkinson's Disease (“PD”).
Mitokinin’s lead pipeline compound is a selective PINK1 activator that addresses mitochondrial dysfunction, which plays an instrumental role in the pathogenesis and progression of PD. Mutations in the PINK1 gene can cause a loss of the PINK1 function, which can result in familial forms of PD. Targeting the PINK1 gene can provide a novel approach for treating PD. Pre-clinical data has shown that the compound can selectively enhance the active form of the PINK1 gene, which amends mitochondrial damage and re-instates mitochondrial function
The candidate, if successfully developed, could be a potential new treatment option for PD. Therapies available to treat PD presently reduce the symptoms of the disease but none prevent the progression of the disease.
Year to date, AbbVie’s shares have lost 8.8% against the industry’s 2.9% rise.
Image Source: Zacks Investment Research
For the deal, AbbVie is making a payment of $110 million to Mitokinin shareholders who will also remain eligible for potential development/commercial milestone payments of up to $545 million
The acquisition, if successfully closed, will strengthen AbbVie’s neuroscience pipeline.
AbbVie’s neuroscience portfolio includes mature drugs like Vraylar and Botox as well as newer drugs like Ubrelvy and Qulipta. While Vraylar is approved for schizophrenia and manic or mixed episodes associated with bipolar I disorder, Botox is approved for several neuroscience indications including chronic migraine, and spastic disorders among others. AbbVie’s neuroscience drugs generated sales of $3.1 billion in the first half of 2023, up 13.8% year over year.
AbbVie also has another PD candidate in its neuroscience pipeline called ABBV-951 for treating motor fluctuations in patients with advanced PD. In March this year, the FDA issued a complete response letter (CRL) to AbbVie’s new drug application (“NDA”) seeking approval for ABBV-951.
ABBV-951 is a solution of carbidopa and levodopa prodrugs, which are the standard of care for PD patients. ABBV-951 has been designed to offer continuous subcutaneous delivery of CD/LD prodrugs through a pump device and offer a better patient experience. In the CRL, the FDA has asked for some extra information about the pump device used to administer the medicine. The FDA has not requested any additional efficacy/safety studies.
Zacks Rank & Key Picks
AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie Inc. Price and Consensus
AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote
Some top-ranked drug/biotech companies worth considering are Alpine Immune Sciences , Aurinia Pharmaceuticals (AUPH - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, the consensus estimate for Alpine Immune Sciences’ 2023 loss has narrowed from $1.43 per share to $1.18 per share, while the same for 2024 has narrowed from $1.73 per share to $1.47 per share. Year to date, shares of Alpine Immune Sciences have rallied 65.5%.
ALPN’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative earnings surprise of 79.65%.
In the past 60 days, the loss per share estimate for Aurinia Pharmaceuticals for 2023 has narrowed from 64 cents per share to 58 cents per share, while that for 2024 has narrowed from 37 cents to 27 cents. Year to date, shares of Aurinia Pharmaceuticals have gained 68.5%.
Earnings of Aurinia Pharmaceuticals beat estimates in all the last four quarters, delivering an earnings surprise of 45.61% on average.
In the past 60 days, the Zacks Consensus Estimate for Corcept’s earnings has increased from 75 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 81 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 30.4% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average earnings surprise of 6.99%.